|
1. BIOLOGIE
|
|
|
|
|
Glioblastoma Study Highlights Sex Differences in Brain Cancer [NCI]
|
|
|
|
|
|
An analysis of the differentially expressed genes in the clusters showed that “survival in males was most significantly determined by genes that regulate cell division,” Dr. Rubin said. For survival in females, the most important pathway involved the expression of genes called integrins, which, he added, are involved in the spread of tumors.
|
|
|
|
|
|
|
3.1 PRÉVENTION - TABAC
|
|
|
|
|
3.1.1 PRÉVENTION - TABAC - E-CIGS
|
|
|
Vaping twice as likely as gum to help smokers quit, research finds [The Guardian]
|
|
|
|
|
|
The research, focused on nearly 900 long-term smokers seeking NHS help to quit, was hailed as a landmark by experts in public health in the UK who believe e-cigarettes have already helped bring down the smoking rate. However, there was less enthusiasm in the United States, where there is concern that vaping nicotine is addictive and may cause children to start smoking.
|
|
|
|
|
|
|
|
|
|
E-cigs outperform patches and gums in quit-smoking study [AP]
|
|
|
|
|
|
In the new study, researchers tracked nearly 900 middle-age smokers who were randomly assigned to receive either e-cigarettes or nicotine replacement products, including patches, gums and lozenges. After one year, 18 percent of e-cigarette users were smoke-free, versus 9.9 percent of those using the other products.
|
|
|
|
|
|
|
The Dangerous Flavors of E-Cigarettes [NEJM]
|
|
|
|
|
|
The public health problem that e-cigarettes can help solve— by helping people who are users of combustible tobacco products stop smoking by switching to vaping — is adequately addressed by liquids that are not flavored to appeal to adolescents. We urge the FDA to use its statutory powers in regulating nicotine delivery devices to take the bold step of removing these flavored products from the market.
|
|
|
|
|
|
|
3.2 PRÉVENTION - OBÉSITÉ
|
|
|
|
4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC
|
|
|
|
4.12 BIOPSIES LIQUIDES
|
|
|
|
5. TRAITEMENTS
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
|
|
|
5.10 TRAITEMENTS - ESSAIS
|
|
|
|
|
|
5.12 IMMUNOTHÉRAPIES
|
|
|
It Was Supposed to Work: Managing Disappointment When Promising Treatments Fail [ASCO Connection]
|
|
|
|
|
|
Yet, in all our talk of this breakthrough and our excitement in both the research and standard use of these agents, I think we’ve oversold its impact. It seems every woman facing a cancer diagnosis I meet for the first time wants immunotherapy. There’s an assumption that all are benefitting, and that it’s a less toxic alternative to standard chemotherapy. Yet, when it comes to most gynecologic and breast cancers, that’s not true.
|
|
|
|
|
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
|
|
|
|
5.12.5 IMMUNOTHÉRAPIES - PHARMA
|
|
|
|
5.2 PHARMA
|
|
|
|
5.3 TRAITEMENTS - FDA, EMA, NICE...
|
|
|
|
|
|
6.6 PUBLICATIONS
|
|
|
Can a “nudge” stop researchers from using the wrong cell lines? [Retraction Watch]
|
|
|
|
|
|
Among more than 300,000 cell line names in more than 150,000 articles, Bandrowski and her colleagues “estimate that 8.6% of these cell lines were on the list of problematic cell lines, whereas only 3.3% of the cell lines in the 634 papers that included RRIDs were on the problematic list,” suggesting “that the use of RRIDs is associated with a lower reported use of problematic cell lines.”
|
|
|
|
|
|
|
|
6.7.2 APPLIS
|
|
|